# Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .

> **NCT06632522** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Tsinghua Chang Gung Hospital** · enrollment: 46 (estimated)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** radiotherapy combined with Camrelizumab and Apatinib

## Key facts

- **NCT ID:** NCT06632522
- **Lead sponsor:** Beijing Tsinghua Chang Gung Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-20
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06632522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06632522, "Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06632522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*